» Articles » PMID: 11320935

Neo-adjuvant Therapy Improves Resectability Rates for Colorectal Liver Metastases

Overview
Specialty General Surgery
Date 2001 Apr 26
PMID 11320935
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Liver resection improves survival in selected patients with colorectal liver metastases. However, the majority of patients with colorectal liver metastases have inoperable disease at presentation. Neo-adjuvant therapy (systemic or regional chemotherapy and interstitial laser therapy) used singly or in combination may convert a selected group of patients with irresectable liver metastases into an operable state.

Patients And Methods: We report a series of patients with initially inoperable multiple colorectal liver metastases who became operable after neo-adjuvant therapy. Operability was defined as unilateral disease limited to the liver. Twelve patients (7 female, 5 male, median age 57 years, range 38-69 years) with multiple inoperable colorectal liver metastases (8 synchronous, 4 metachronous) were initially treated with systemic chemotherapy (n = 7), hepatic arterial chemotherapy (n = 2) and chemotherapy plus interstitial laser therapy (n = 3).

Results: In all cases, a significant response was achieved which enabled subsequent liver resection to be undertaken. There was only one postoperative complication (8%) and no peri-operative deaths. 3 patients were operated on within the last 12 months and are still alive. Of the remainder, 1 died within 1 year with recurrent disease. The remaining patients have a median survival of 2.5 years, range 1.39-4 years.

Conclusions: These results are similar to those reported for patients undergoing resection for operable metastases without neo-adjuvant therapy. Aggressive multimodality treatment of colorectal liver metastases in specialised centres may improve the resectability rates and survival in a selected group of patients.

Citing Articles

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy.

Yeh Y, Tsai H, Chen Y, Su W, Chen P, Chang T Oncol Res. 2023; 30(2):65-76.

PMID: 37305327 PMC: 10208060. DOI: 10.32604/or.2022.026659.


Use of perioperative chemotherapy in colorectal cancer metastatic to the liver.

Symonds L, Cohen S Gastroenterol Rep (Oxf). 2019; 7(5):301-311.

PMID: 31687149 PMC: 6821343. DOI: 10.1093/gastro/goz035.


Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.

Leimkuhler M, Hemmer P, Reyners A, de Groot D, van Ginkel R, Been L World J Surg Oncol. 2019; 17(1):14.

PMID: 30635070 PMC: 6330449. DOI: 10.1186/s12957-018-1554-8.


Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.

Baba K, Oshita A, Kohyama M, Inoue S, Kuroo Y, Yamaguchi T World J Gastroenterol. 2015; 21(6):1982-8.

PMID: 25684967 PMC: 4323478. DOI: 10.3748/wjg.v21.i6.1982.


Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients.

Bacchetti S, Pasqual E, Crozzolo E, Pellarin A, Cagol P Med Devices (Auckl). 2012; 2:31-40.

PMID: 22915912 PMC: 3417858. DOI: 10.2147/mder.s4036.


References
1.
Scheele J . Hepatectomy for liver metastases. Br J Surg. 1993; 80(3):274-6. DOI: 10.1002/bjs.1800800302. View

2.
MARTIN Jr J, Oconnell M, Wieand H, Fitzgibbons Jr R, Mailliard J, Rubin J . Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990; 125(8):1022-7. DOI: 10.1001/archsurg.1990.01410200086013. View

3.
Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D . Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224(4):509-20; discussion 520-2. PMC: 1235414. DOI: 10.1097/00000658-199610000-00009. View

4.
Chang A, Schneider P, Sugarbaker P, Simpson C, Culnane M, Steinberg S . A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987; 206(6):685-93. PMC: 1493315. DOI: 10.1097/00000658-198712000-00001. View

5.
Tuttle T, Curley S, Roh M . Repeat hepatic resection as effective treatment of recurrent colorectal liver metastases. Ann Surg Oncol. 1997; 4(2):125-30. DOI: 10.1007/BF02303794. View